Welcome to DialogClassic Web(tm)

```
 Dialog level 05.09.03D
Last logoff:  23dec05 10:33:46
Logon file001 28dec05 11:31:52
          *** ANNOUNCEMENT ***
                    ***
NEW FILES RELEASED
***Index Chemicus (File 302)
***Inspec (File 202)
***Physical Education Index (File 138)
***Computer and Information Systems Abstracts (File 56)
***Electronics and Communications Abstracts (File 57)
***Solid State and Superconductivity Abstracts (File 68)
***ANTE: Abstracts in New Technologies (File 60)
                    ***
RELOADS COMPLETED
*** The 2005 reload of the CLAIMS files (Files 340, 341, 942)
is now available online.

RESUMED UPDATING
***ERIC (File 1)
                    ***
Chemical Structure Searching now available in Prous Science Drug
Data Report (F452), Prous Science Drugs of the Future (F453),
IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein
Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus (File 302).
                    ***
     >>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
     >>>    of new databases, price changes, etc.      <<<
                    ****
 * * *

File   1:ERIC 1966-2005/Nov
       (c) format only 2005 Dialog

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
?

B 155, 5, 73, 34, 434
       28dec05 11:33:32 User290558 Session D5.1
            $0.81    0.230 DialUnits File1
     $0.81  Estimated cost File1
     $0.53  INTERNET
     $1.34  Estimated cost this search
     $1.34  Estimated total session cost   0.230 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R) 1951-2005/Dec 07
         (c) format only 2005 Dialog
 *File 155: Medline has ceased updating as of UD 20051207, until        e
the reload is complete. Please see HELP NEWS 154 for details.
  File   5:Biosis Previews(R) 1969-2005/Dec W4
         (c) 2005 BIOSIS
  File  73:EMBASE 1974-2005/Dec 28
         (c) 2005 Elsevier Science B.V.
  File  34:SciSearch(R) Cited Ref Sci 1990-2005/Dec W4
         (c) 2005 Inst for Sci Info
  File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
```

```
         (c) 1998 Inst for Sci Info

      Set  Items  Description
      ---  -----  -----------
?

S (ANTIBOD? OR HUMAN? B CELL)
>>>File 5 processing for HUMAN? B CELL stopped at HUMAN ANTIHYPERTENSIVE-DR
  UG PHARMACOKINETICS F
        2388884  ANTIBOD?
              0  HUMAN? B CELL
      S1 2388884  (ANTIBOD? OR HUMAN? B CELL)
?

S (GLYCOSYLAT? OR HCN1 OR HCN2 OR HCN3 OR HCN4 OR HCN5)
         164136  GLYCOSYLAT?
            531  HCN1
            538  HCN2
             90  HCN3
            316  HCN4
              8  HCN5
      S2  164978  (GLYCOSYLAT? OR HCN1 OR HCN2 OR HCN3 OR HCN4 OR HCN5)
?

S S1 AND S2
        2388884  S1
         164978  S2
      S3   25483  S1 AND S2
?

S (FC CONSTANT OR (HEAVY OR LIGHT) (W) CHAIN)
              0  FC CONSTANT
         438458  HEAVY
        1349518  LIGHT
        1629061  CHAIN
         152302  (HEAVY OR LIGHT)(W)CHAIN
      S4  152302  (FC CONSTANT OR (HEAVY OR LIGHT) (W) CHAIN)
?


Set     Items   Description
S1    2388884   (ANTIBOD? OR HUMAN? B CELL)
S2     164978   (GLYCOSYLAT? OR HCN1 OR HCN2 OR HCN3 OR HCN4 OR HCN5)
S3      25483   S1 AND S2
S4     152302   (FC CONSTANT OR (HEAVY OR LIGHT) (W) CHAIN)
?

S S3 AND S4
           25483  S3
          152302  S4
      S5     716  S3 AND S4
?

S S5 AND CH1
             716  S5
            2138  CH1
      S6       6  S5 AND CH1
?

S S5 AND HLL2
```

```
             716  S5
              98  HLL2
      S7       4  S5 AND HLL2
?


Set     Items   Description
S1    2388884   (ANTIBOD? OR HUMAN? B CELL)
S2     164978   (GLYCOSYLAT? OR HCN1 OR HCN2 OR HCN3 OR HCN4 OR HCN5)
S3      25483   S1 AND S2
S4     152302   (FC CONSTANT OR (HEAVY OR LIGHT) (W) CHAIN)
S5        716   S3 AND S4
S6          6   S5 AND CH1
S7          4   S5 AND HLL2
?

S S6 OR S7
               6  S6
               4  S7
      S8      10  S6 OR S7
?

RD S8
      S9       7  RD S8  (unique items)
?

T/MEDIUM,K/1-7

  9/K/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2005 Dialog. All rts. reserv.

12902849   PMID: 10849371
 The amino acid sequence of a monoclonal gamma 3-heavy chain from a
 patient with articular gamma-heavy chain deposition disease.
  Danevad M; Sletten K; Gaarder P I; Mellbye O J; Husby G
  Department of Biochemistry/Biotechnology Center of Oslo, Norway.
  Scandinavian journal of immunology (ENGLAND)   Jun 2000,  51  (6)  p602-6
,  ISSN 0300-9475   Journal Code: 0323767
  Publishing Model Print
  Document type: Case Reports; Journal Article
  Languages: ENGLISH
  Main Citation Owner: NLM
  Record type: MEDLINE; Completed

  The amino acid sequence of a monoclonal gamma 3- heavy  chain  from a
 patient with articular gamma- heavy  chain  deposition disease.
  ... present in serum and urine of the first reported case (patient G. L.)
of synovial  heavy  chain  deposition disease. The protein was heavily
deleted and consisted of the hinge, in addition to...

...CH3 domains, in a dimeric form, thus lacking its variable domain as well
as the CH1 domain. The sequence was consistent with the gamma 3 subclass
(gamma 3GL). Gm typing revealed...

... residues Pro123, Phe128, Thr171 and Phe268 in gamma 3GL. Furthermore,
the gamma 3GL molecule was glycosylated at Asn in position 129. Finally,
the gamma 3GL protein was shown to contain a...
  Descriptors:  *Antibodie s, Monoclonal--chemistry--CH; * Heavy  Chain
 Disease--immunology--IM; *Immunoglobulins, Heavy - Chain --chemistry--CH;
```

*Immunoglobulins, gamma-Chain--chemistry--CH; Amino Acid Sequence; Antibodies , Monoclonal--metabolism--ME; Carbohydrates--analysis--AN; Complement Activation--immunology--IM; Heavy Chain Disease--metabolism --ME; Humans; Immunoglobulin Gm Allotypes--chemistry--CH; Immunoglobulins, Heavy - Chain --metabolism--ME; Immunoglobulins, gamma-Chain--metabolism --ME; Middle Aged; Molecular Sequence Data; Synovial Membrane--immunology ...

Chemical Name: Antibodies , Monoclonal; Carbohydrates; Immunoglobulin Gm Allotypes; Immunoglobulins, Heavy - Chain ; Immunoglobulins, gamma-Chain

9/K/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

12094214 PMID: 9393962

Glycosylation is influential in murine IgG3 self-association.

Panka D J

Department of Microbiology, Boston University Medical School, MA 02118, U.S.A.

Molecular immunology (ENGLAND) Jun 1997, 34 (8-9) p593-8, ISSN 0161-5890 Journal Code: 7905289

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Glycosylation is influential in murine IgG3 self-association.

In mice and humans, antibodies of the IgG3 isotype are unique in that they spontaneously self-associate. A consequence is...

... murine IgG3 self-association. A region of the CH3 domain that is unique to IgG3 antibodies is the presence of an extra glycosylation site at residues 471-473. It is known that glycosylation greatly influences solubility. It has also been shown by X-ray crystallography that glycosylated residues (specifically sialic acid) are influential in the contacts of the CH1 to CH2 as well as the CH2 to CH2 domains in a human IgG1 antibody . These findings provided evidence that a direct interaction exists between the glycosylated residues and other residues within the constant and/or variable domains. It was, therefore, important to determine whether the glycosylated residue in the CH3 domain of the IgG3 constant region is influential in self-association. We have found that removing the glycosylation site by site-directed mutagenesis of an IgG3 RF significantly reduced the self-associating ability of this antibody .

; Animals; Cloning, Molecular; Glycosylation ; Humans; Immunoglobulin G --genetics--GE; Immunoglobulin Variable Region--genetics--GE; Immunoglobulins, Heavy - Chain --genetics--GE; Mice; Mutagenesis, Site-Directed; Protein Conformation

Chemical Name: Immunoglobulin G; Immunoglobulin Variable Region; Immunoglobulins, Heavy - Chain ; Rheumatoid Factor

9/K/3 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

11358173 PMID: 8643111

Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.

Leung S O; Goldenberg D M; Dion A S; Pellegrini M C; Shevitz J; Shih L B; Hansen H J
Immunomedics, Inc., Morris Plains, NJ 07950, USA.
Molecular immunology (ENGLAND) Dec 1995, 32 (17-18) p1413-27, ISSN 0161-5890 Journal Code: 7905289
Contract/Grant No.: CA 39841; CA; NCI
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody , LL2.

The murine monoclonal antibody , LL2, is a B-cell (CD22)-specific IgG2a which has been demonstrated to be clinically significant in the radioimmunodetection of non-Hodgkin's B-cell lymphoma. The antibody carries a variable region-appended glycosylation site in the light chain and is rapidly internalized upon binding to Raji target cells. Humanization of LL2 was carried...

...FR) 1, 2 and 3, and the NEWM FR4 as the scaffold for grafting the heavy chain complementarity determining regions (CDRs), and REI FRs for that of light chains. The light chain glycosylation site, however, was not included. Construction of the CDR-grafted variable regions was accomplished by...

... that involved long DNA oligonucleotide synthesis and the polymerase chain reaction (PCR). The humanized LL2 (hLL2), lacking light chain variable region glycosylation , exhibited immunoreactivities that were comparable to that of chimeric LL2 (cLL2), which was shown previously...

... the VK-appended oligosaccharides found in mLL2 are not necessary for antigen binding. Moreover, the hLL2 retained its ability to be internalized into Raji cells at a rate similar to its...
Descriptors: *Antibodie s, Neoplasm--biosynthesis--BI; *Antigens, CD --genetics--GE; *Antigens, Differentiation, B-Lymphocyte--genetics--GE; *Cell Adhesion...
; Amino Acid Sequence; Animals; Antibodies , Neoplasm--chemistry--CH; Antibodies , Neoplasm--genetics--GE; Antibody Specificity--genetics--GE; Base Sequence; Chimeric Proteins--chemistry--CH; DNA Primers; Humans; Leukemia, B-Cell...
Chemical Name: Antibodies , Neoplasm; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; CD22 antigen; Cell Adhesion Molecules; Chimeric Proteins; DNA...

9/K/4 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

09148246 PMID: 2226804
Structural features of the McPC603 Fab fragment not defined in the X-ray structure.
Skerra A; Glockshuber R; Pluckthun A
Genzentrum der Universitat Munchen, Max-Planck-Institut fur Biochemie, Martinsried, FRG.
FEBS letters (NETHERLANDS) Oct 1 1990, 271 (1-2) p203-6, ISSN 0014-5793 Journal Code: 0155157
Publishing Model Print

Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

The proteolytic Fab fragment of the well characterized antibody McPC603 was compared to the recombinant Fab fragment, which was obtained in functional form from...

... system [(1989) Methods Enzymol. 178, 497-515]. We found evidence that the proteolytic fragment is glycosylated at Asn H160 in the CH1 domain, where additional electron density had been observed in the crystal structure [J. Mol. Biol. 190, 593-604]. In addition, its heavy chain is about 30 amino acids longer than visible in the electron density and thus contains...

... aware of these structural features of McPC603 in folding studies and some comparative analyses of antibody structures.
; Amino Acid Sequence; Antibodies , Bacterial--immunology--IM; Molecular Sequence Data; Recombinant Proteins--immunology--IM; X-Ray Diffraction
Chemical Name: Antibodies , Bacterial; Carrier Proteins; Crp protein, rat; Immunoglobulins; Immunoglobulins, Fab; Myeloma Proteins; Recombinant Proteins; myeloma immunoglobulins

9/K/5 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0014003603 BIOSIS NO.: 200200597114
Construction and functional analysis of a whole human IgG antibody against Candida mannan
AUTHOR: Zhang M X (Reprint); Parren P W; Itatani C (Reprint); Adeseun A; Nyeche C; Kozel T R
AUTHOR ADDRESS: California State University, Long Beach, CA, USA**USA
JOURNAL: Abstracts of the General Meeting of the American Society for Microbiology 102 p211-212 2002 2002
MEDIUM: print
CONFERENCE/MEETING: 102nd General Meeting of the American Society for Microbiology Salt Lake City, UT, USA May 19-23, 2002; 20020519
SPONSOR: American Society for Microbiology
ISSN: 1060-2011
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

Construction and functional analysis of a whole human IgG antibody against Candida mannan

ABSTRACT: Appreciable amounts of anti-Candida mannan antibodies are present in sera from normal individuals without regard to gender, race, and age. However, the significance and biological functions of natural antimannan antibodies are poorly understood. One approach to this question is to generate recombinant human anti-Candida antibodies . The purpose of this study was to convert a recombinant antimannan Fab (M1) to a full length IgG1 antibody with an expression vector pIgG1. M1 VL-CL gene was subcloned into pIgG1 and M1 VH- CH1 gene was ligated with the gene for the constant domains of the IgG1 heavy chain contained in pIgG1. Stoichiometric expression of the light and heavy chain genes is under separate control of a human cytomegalovirus promoter/enhancer.

Whole antibody molecules were produced with a Chinese hamster ovarian cell line and purified with protein A. The IgG1 subclass identity of the antibody was confirmed with an IgG1-specific monoclonal antibody by ELISA. The whole IgG1 antibody retained the mannan-binding specificity of M1 as determined in ELISA with chemically purified mannan...

...complement C3 fragments to Candida yeast cells in a dose dependent manner, suggesting that the antibody was properly glycosylated . Furthermore, M1g1 enhanced both ingestion/binding of Candida yeast cells by human monocyte-derived macrophages...

...Fc and Fc-receptor interactions. Thus, M1g1 appears to be the first functional recombinant human antibody reactive with Candida mannan.
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: ...anti-Candida mannan antibodies --...

...whole human immunoglobulin G antibody --

9/K/6 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

12530352 Genuine Article#: 776VT No. References: 54
Title: Site-specific N-glycosylation of chicken serum IgG
Author(s): Suzuki N (REPRINT) ; Lee YC
Corporate Source: Johns Hopkins Univ,Dept Biol,Baltimore//MD/21218 (REPRINT); Johns Hopkins Univ,Dept Biol,Baltimore//MD/21218
Journal: GLYCOBIOLOGY, 2004, V14, N3 (MAR), P275-292
ISSN: 0959-6658 Publication date: 20040300
Publisher: OXFORD UNIV PRESS INC, JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

Title: Site-specific N- glycosylation of chicken serum IgG
...Abstract: in its heavy (H) chain. In chicken IgG, each H-chain contains two potential N- glycosylation sites located on CH2 and CH3 domains. To clarify characteristics of N- glycosylation on avian IgG, we analyze N-glycans from chicken serum IgG by derivatization with 2...

...serum IgG was digested with papain and separated into Fab [containing variable regions (VH + VL) + CH1 + CL] and Fc (containing CH3 + CH4) fragments. Con A stained only Fc (CH3 + CH4) and...
...mannose-type oligosaccharides, whereas chicken CH2 domain contained only complex-type N-glycans. The N- glycosylation pattern on avian IgG is more analogous to that in mammalian IgE than IgG, presumably...
...Identifiers--ASPARAGINE-LINKED OLIGOSACCHARIDES; 2-DIMENSIONAL SUGAR MAP; YOLK ANTIBODY IGY; PIGEON EGG-WHITE; HEAVY - CHAIN ; ENDOPLASMIC-RETICULUM; MAJOR GLYCOPROTEINS; MAPPING TECHNIQUE; GLYCAN STRUCTURES; FC FRAGMENT

9/K/7 (Item 2 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

01472748 Genuine Article#: HB535 No. References: 27
Title: FRANKLIN DISEASE - IG-GAMMA-2 H-CHAIN MUTANT BUR
Author(s): PRELLI F; FRANGIONE B
Corporate Source: NYU MED CTR,DEPT PATHOL/NEW YORK//NY/10016

Journal: JOURNAL OF IMMUNOLOGY, 1992, V148, N3 (FEB 1), P949-952
Language: ENGLISH Document Type: ARTICLE (Abstract Available)

...Abstract: of a complete V region, hinge, CH2, and CH3 domains. There is one deletion, the CH1 domain, which includes the cysteine residue bridging the H to L chain. Although the V...

...position 11, two unique cysteine residues in the second complementarity determining region (CDR2), and three glycosylation sites, two of which are located in the CDR2 and CDR3 regions. These distinctive characteristics...
...Identifiers-- HEAVY - CHAIN ; IMMUNOGLOBULIN GENES; MOLECULAR DEFECT; PROTEIN; SEQUENCE; ACID; FRAGMENT
Research Fronts: 90-0715 001 (ANTIBODY REPERTOIRE OF EARLY HUMAN B-CELLS; AUTOIMMUNE MICE; VK GENE FAMILIES; HEAVY - CHAIN VARIABLE REGIONS; SYSTEMIC LUPUS-ERYTHEMATOSUS; SOMATIC MUTATION)
90-3110 001 (IDENTIFICATION OF FRAGMENTS; CORTICOSTEROIDS INCREASE...
?

Set	Items	Description
S1	2388884	(ANTIBOD? OR HUMAN? B CELL)
S2	164978	(GLYCOSYLAT? OR HCN1 OR HCN2 OR HCN3 OR HCN4 OR HCN5)
S3	25483	S1 AND S2
S4	152302	(FC CONSTANT OR (HEAVY OR LIGHT) (W) CHAIN)
S5	716	S3 AND S4
S6	6	S5 AND CH1
S7	4	S5 AND HLL2
S8	10	S6 OR S7
S9	7	RD S8 (unique items)

?